Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Diversifying in biotech

Article Abstract:

Investors seeking diversification often turn to mutual funds (unit trusts in the UK and elsewhere) and biotech investors can use various tools to spread their risks as well. Though there are two commonly used indexes of US biotech stock market performance such as the American Stock Exchange Biotechnology Index and the Nasdaq Biotechnology Index, biotech investors have one major index investing option.

Author: Jacobs, Tom
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Forecasts, trends, outlooks, Investment Offices, Security brokers and dealers, Mutual Fund Mgmt Companies, Portfolio Management, Securities & Commodities Services, Securities, Commodity Contracts, and Other Financial Investments and Related Activities, Analysis, Evaluation, Forecasts and trends, Risk factors, Securities industry, Market trend/market analysis, Mutual funds, Nasdaq Stock Market Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Does biotech M&A benefit investors?

Article Abstract:

The effect of merging as a benefit to investors is detailed. It is observed that the best performing companies do not merge and if a company of any size is in trouble, it certainly is better for employees and their communities if they merge than not, for investors the expectations for such mergers are so high that the results are usually mediocre or worse.

Author: Jacobs, Tom
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Investor relations

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Biotech IPOs: handle with care

Article Abstract:

Tom Jacob's views on biotechnology investments are discussed. The initial public offerings (IPOs) are financing events for companies and so no great opportunities are left for investors.

Author: Jacobs, Tom
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
Biological Product (except Diagnostic) Manufacturing, Molecular Biological Products, Venture Analysis, Finance, Beliefs, opinions and attitudes, Business enterprises, Going public (Securities), Initial public offerings, Company public offering, Biotechnology, Company financing, Jacob, Tom

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Biotechnology industry, Biotechnology industries, Company investment, Investments
Similar abstracts:
  • Abstracts: The number on biotech indexes. Putting biotech risk in its place. Going short on biotech
  • Abstracts: Canada's bumper biotech budget. Angel investors shy away from biotech
  • Abstracts: Conclusions: Promoting biotechnology innovation in developing countries. Biotechnology and the UN's millennium development goals
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.